Related Experiment Video
Updated: Mar 27, 2026

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
Published on: August 2, 2018
Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling
Sebastian K Wandinger1, Idoya Lahortiga2,3, Kris Jacobs2,3
1Evotec (München) GmbH, Martinsried, Germany.
Abstract:
The four members of the epidermal growth factor receptor (EGFR/ERBB) family form homo- and heterodimers which mediate ligand-specific regulation of many key cellular processes in normal and cancer tissues. While signaling through the EGFR has been extensively studied on the molecular level, signal transduction through ERBB3/ERBB4 heterodimers is less well understood. Here, we generated isogenic mouse Ba/F3 cells that express full-length and functional membrane-integrated ERBB3 and ERBB4 or ERBB4 alone, to serve as a defined cellular model for biological and phosphoproteomics analysis of ERBB3/ERBB4 signaling. ERBB3 co-expression significantly enhanced Ba/F3 cell proliferation upon neuregulin-1 (NRG1) treatment. For comprehensive signaling studies we performed quantitative mass spectrometry (MS) experiments to compare the basal ERBB3/ERBB4 cell phosphoproteome to NRG1 treatment of ERBB3/ERBB4 and ERBB4 cells. We employed a workflow comprising differential isotope labeling with mTRAQ reagents followed by chromatographic peptide separation and final phosphopeptide enrichment prior to MS analysis. Overall, we identified 9686 phosphorylation sites which could be confidently localized to specific residues. Statistical analysis of three replicate experiments revealed 492 phosphorylation sites which were significantly changed in NRG1-treated ERBB3/ERBB4 cells. Bioinformatics data analysis recapitulated regulation of mitogen-activated protein kinase and Akt pathways, but also indicated signaling links to cytoskeletal functions and nuclear biology. Comparative assessment of NRG1-stimulated ERBB4 Ba/F3 cells revealed that ERBB3 did not trigger defined signaling pathways but more broadly enhanced phosphoproteome regulation in cells expressing both receptors. In conclusion, our data provide the first global picture of ERBB3/ERBB4 signaling and provide numerous potential starting points for further mechanistic studies.
Insights
The epidermal growth factor receptor (EGFR/ERBB) family
Area of Science:
- Cellular Biology
- Molecular Signaling
- Cancer Research
Background:
- The epidermal growth factor receptor (EGFR/ERBB) family plays crucial roles in cellular processes, with EGFR signaling well-understood.
- Signal transduction via ERBB3/ERBB4 heterodimers remains less characterized.
- Understanding ERBB3/ERBB4 signaling is vital for cancer research and therapeutic development.
Purpose of the Study:
- To investigate the signaling pathways mediated by ERBB3/ERBB4 heterodimers.
- To establish a defined cellular model for studying ERBB3/ERBB4 signaling.
- To perform a global phosphoproteomics analysis of ERBB3/ERBB4 signaling.
Main Methods:
- Generated isogenic mouse Ba/F3 cells expressing ERBB3/ERBB4 or ERBB4 alone.
- Utilized quantitative mass spectrometry (MS) with mTRAQ labeling for phosphoproteomics.
- Performed differential isotope labeling, peptide separation, and phosphopeptide enrichment.
Main Results:
- Identified 9686 phosphorylation sites, with 492 significantly altered upon neuregulin-1 (NRG1) treatment in ERBB3/ERBB4 cells.
- Confirmed regulation of MAPK and Akt pathways, and identified links to cytoskeletal and nuclear functions.
- ERBB3 broadly enhanced phosphoproteome regulation, rather than triggering specific pathways, in NRG1-stimulated cells.
Conclusions:
- This study provides the first global phosphoproteomic landscape of ERBB3/ERBB4 signaling.
- ERBB3 co-expression significantly enhances cell proliferation and broadly impacts signaling in response to NRG1.
- The findings offer numerous starting points for future mechanistic studies of ERBB3/ERBB4 signaling in normal and cancer tissues.

